Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
03 2020
Historique:
received: 22 05 2019
revised: 14 09 2019
accepted: 15 10 2019
pubmed: 28 10 2019
medline: 24 6 2021
entrez: 25 10 2019
Statut: ppublish

Résumé

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P= .016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P = .022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P< .0001) were significantly predictive of a worse NRM. In our large cohort, both comorbidities, evaluated by the original HCT-CI score, and chronological age significantly affected NRM. Thus, age should be part of the transplant decision-making process and should be integrated in future scoring systems predicting outcomes of HSCT in MDSs.

Identifiants

pubmed: 31647984
pii: S1083-8791(19)30672-X
doi: 10.1016/j.bbmt.2019.10.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

451-457

Informations de copyright

Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Auteurs

Martin Carré (M)

CHU Grenoble-Alpes, Grenoble, France. Electronic address: mcarre1@chu-grenoble.fr.

Raphaël Porcher (R)

Hôpital de l'Hôtel Dieu, Paris, France.

Jürgen Finke (J)

University of Freiburg, Freiburg, Germany.

Gerhard Ehninger (G)

Universitaetsklinikum Dresden, Dresden, Germany.

Linda Koster (L)

European Group for Blood and Marrow Transplantation Data Office, Leiden, The Netherlands.

Dietrich Beelen (D)

University Hospital, Essen, Germany.

Arnold Ganser (A)

Hannover Medical School, Hannover, Germany.

Liisa Volin (L)

HUCH Comprehensive Cancer Center, Helsinki, Finland.

Sara Lozano (S)

Hospital Universitario Ramon y Cajal, Madrid, Spain.

Lone Friis (L)

Rigshospitalet, Copenhagen, Denmark.

Mauricette Michallet (M)

Centre Léon Bérard, Lyon, France.

Johanna Tischer (J)

Klinikum Grosshadern, Munich, Germany.

Eduardo Olavarria (E)

Imperial College Healthcare NHS Trust, London, UK.

Maria Jesús Pascual Cascon (MJP)

Hospital Regional de Málaga, Málaga, Spain.

Simona Iacobelli (S)

University of Tor Vergata, Rome, Italy.

Yener Koc (Y)

Medical Park Hospitals, Antalya, Turkey.

Pavel Jindra (P)

Charles University Hospital, Pilsen, Czech Republic.

Mutlu Arat (M)

Florence Nightingale Sisli Hospital, Istanbul, Turkey.

Theo de Witte (T)

Radboud University Medical Centre-Nijmegen, Nijmegen, The Netherlands.

Ibrahim Yakoub Agha (I)

Unité d'Allogreffe, Maladies du sang, Lille, France.

Nicolaus Kröger (N)

University Hospital Eppendorf, Hamburg, Germany.

Marie Robin (M)

Hopital St. Louis, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH